On 16 January 2014, orphan designation (EU/3/13/1224) was granted by the European Commission to Hope Pharmaceuticals, Ltd., United Kingdom, for sodium nitrite for the treatment of aneurysmal subarachnoid haemorrhage.
The sponsor’s address was updated in March 2019.
The sponsorship was transferred to Hope Pharmaceuticals Limited, Ireland, in August 2019.
|Disease / condition||
Treatment of aneurysmal subarachnoid haemorrhage
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.